PremiumCompany AnnouncementsRecursion Pharmaceuticals’ Earnings Call: Balancing Success and Challenges Options Volatility and Implied Earnings Moves Today, May 05, 2025 Recursion Pharmaceuticals Reports Q1 Results and Strategy Update PremiumMarket NewsBTIG Analyst Sees Tempus AI (TEM) as “Significant Free Call Option” with 48% Upside Recursion and HealthVerity announce agreement Largest borrow rate increases among liquid names PremiumThe FlyRecursion Pharmaceuticals, Enamine release new tools in its AI/ML platform Recursion announces first patient dosed in Phase 1 REC-3565 study Strategic Positioning and Operational Resilience Justify Buy Rating for Recursion Pharmaceuticals 
